Biotech Values

[dewophile]

REGN seems to have a lot riding on the readout of the high dose phase 3 study which I think is later this year
I'm not following this space much so I am not sure how much the uveitis/inflammation w Vabysmo will impact adoption vs Eylea.
Dosing intervals alone were enough to propel Eylea to commercial success that exceeded everyone's expectations (including yours IIRC), so the ability for 80% of patients to get dosing less frequently than Elyea could be a meaningful differentiator